<DOC>
	<DOC>NCT00759070</DOC>
	<brief_summary>This study is an open-label, randomized, pilot comparison of the effects of either lopinavir/ritonavir or efavirenz in combination with tenofovir plus emtricitabine on cholesterol metabolism, mitochondrial functioning and immune response in 50 naive HIV patients after 48 weeks.</brief_summary>
	<brief_title>Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Chronic HIV1 infection Age 18 or above Antiretroviralnaive Criteria for antiretroviral therapy in accordance with current guidelines Plasma LDLcholesterol below 190 mg/dL Not receiving lipidlowering agents Written informed consent Use of phytosterolenriched food previous month. Pregnancy or breastfeeding Cardiovascular disease Secondary Hypercholesterolemia Plasma creatinine above 1,2 mg/dL) Aminotransferases above 5 times ULN Current treatment for hepatitis C coinfection Diabetes mellitus (fasting glycemia &gt; 124 mg/dL) Illegal drug use or alcohol abuse Active AIDSdefining opportunistic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Treatment Na√Øve</keyword>
</DOC>